SCHEMBL356233

SCHEMBL356233

COC1CCCN(C)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3436862 1.00
SCHEMBL8241010 1.00
SCHEMBL8298892 0.85 SMN1; SMN2 (0.39)
SCHEMBL3436804 0.85
SCHEMBL254092 0.85
SCHEMBL8224168 0.85
Methane SCHEMBL22180259 0.83
SCHEMBL8298097 0.81 HRH3 (0.40)
SCHEMBL12212555 0.79 SMN1; SMN2 (0.33)
SCHEMBL220278 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103242694-B Low-odor environment-friendly nano pigment ink-jet ink composition JETBEST CORP. (CN) 2014-10-29 CN claimed
CN-103242694-A Low-odor environment-friendly nano pigment ink-jet ink composition JETBEST CORP 2013-08-14 CN claimed
US-20090326220-A1 Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists DILLON MICHAEL PATRICK 2009-12-31 US claimed
US-20260001887-A1 CYCLIN-DEPENDENT KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2026-01-01 US disclosed
US-11874434-B2 Ophthalmic devices comprising photochromic materials with reactive substituents JOHNSON & JOHNSON VISION CARE, INC. (US) 2024-01-16 US disclosed
US-11874434-B2 Ophthalmic devices comprising photochromic materials with reactive substituents JOHNSON & JOHNSON VISION CARE, INC. (US) 2024-01-16 US disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 US disclosed
US-20230348439-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES INC (US) 2023-11-02 US disclosed
US-20230348453-A1 HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2023-11-02 US disclosed
WO-2023205892-A1 CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-11-02 WO disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed
CN-1774435-A 5-membered heterocyclic derivative DAIICHI SEIYAKU CO (JP) 2006-05-17 CN disclosed
CN-1665787-A Process for preparing 7-substituted-3-quinolines and 3-quinol-4-one carbonitriles WYETH CORP (US) 2005-09-07 CN disclosed
CN-1597667-A Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2005-03-23 CN disclosed
CN-1142920-C Quinazoline derivatives and pharmaceutical compositions containing them 2004-03-24 CN disclosed
CN-1258294-A 2-oxoimidazole derivs. BANYU PHARMA CO LTD (JP) 2000-06-28 CN disclosed
CN-1231662-A Quinazoline derivatives and pharmaceutical compositions containing them ZENNECA LTD (GB) 1999-10-13 CN disclosed
CN-1226886-A Arylcycloalkane carboxylic acid esters, their use, pharmaceutical compositions and process for their preparation PHARMACIA & UPJOHN AB (SE) 1999-08-25 CN disclosed